Physician profile
James Michael Conkright
NPI 1548221658
$7,577.38
in general payments reported to CMS, 2019-2025
7 companies · $78.95 in 2025
The $78.95 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $55.18 · 2021: $2,101 · 2022: $589 · 2023: $3,066 · 2024: $114 · 2025: $78.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,544 · Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,543.74 |
| Food and Beverage | $715.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,866.19 | 2019-2022 | |
| Abbvie INC. | $3,219.56 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Botox |
| Merz North America, INC. | $310.36 | 2022 | |
| Galderma Laboratories, L.P. | $124.99 | 2019-2021 | |
| Motiva USA, LLC | $39.44 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $12.11 | 2021 | |
| Sientra, INC. | $4.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Conkright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.